The estimated Net Worth of John G. Aunins is at least $3 Million dollars as of 26 January 2020. John Aunins owns over 12,500 units of Seres Therapeutics Inc stock worth over $110,513 and over the last 9 years he sold MCRB stock worth over $2,889,913. In addition, he makes $0 as Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer at Seres Therapeutics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Aunins MCRB stock SEC Form 4 insiders trading
John has made over 15 trades of the Seres Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 12,500 units of MCRB stock worth $13,125 on 26 January 2020.
The largest trade he's ever made was exercising 187,500 units of Seres Therapeutics Inc stock on 22 July 2016 worth over $90,000. On average, John trades about 15,944 units every 56 days since 2015. As of 26 January 2020 he still owns at least 105,250 units of Seres Therapeutics Inc stock.
You can see the complete history of John Aunins stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Aunins biography
Dr. John G. Aunins Ph.D. serves as Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer of the Company. Prior to joining our Company, Dr. Aunins served on our Scientific Advisory Board from February 2012 to December 2012. From April 1989 to November 2011, Dr. Aunins served in various roles at Merck, most recently as Executive Science Director. At Merck, Dr. Aunins led process and product development teams for six licensed vaccines and multiple vaccine candidates. He is a Fellow of the American Institute for Medical and Biological Engineering and an adjunct Full Professor at the Instituto de Tecnologia Quimica e Biologica in Oeiras, Portugal. Dr. Aunins received his B.S. from the University of Kansas and his Ph.D. in Chemical Engineering from MIT.
How old is John Aunins?
John Aunins is 59, he's been the Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer of Seres Therapeutics Inc since 2012. There are 10 older and 9 younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.
What's John Aunins's mailing address?
John's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Insiders trading at Seres Therapeutics Inc
Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par..., and Health Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.
What does Seres Therapeutics Inc do?
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
What does Seres Therapeutics Inc's logo look like?
Complete history of John Aunins stock trades at Seres Therapeutics Inc
Seres Therapeutics Inc executives and stock owners
Seres Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Eric Shaff,
President, Chief Executive Officer, Director -
Eric D. Shaff M.B.A.,
Pres, CEO & Director -
Thomas DesRosier,
Chief Legal Officer, Executive Vice President and Secretary -
Matthew Henn,
Executive Vice President, Chief Scientific Officer -
Thomas J. DesRosier,
Chief Legal Officer, Exec. VP & Sec. -
Dr. David S. Ege Ph.D.,
Exec. VP & Chief Technology Officer -
Richard Kender,
Independent Director -
Kurt Graves,
Independent Director -
Meryl Zausner,
Independent Director -
Willard Dere,
Independent Director -
Gregory Behar,
Independent Director -
Dennis Ausiello,
Independent Director -
Stephen Berenson,
Independent Chairman of the Board -
David Ege,
Executive Vice President, Chief Technology Officer -
Jayne Gansler,
Chief People Officer, Executive Vice President -
Terri Young,
Executive Vice President, Chief Commercial and Strategy Officer -
Lisa von Moltke,
Executive Vice President, Chief Medical Officer -
Paul Biondi,
Independent Director -
Carlo Tanzi,
Head of Investor Relations and Corporate Communications -
John Aunins,
Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer -
Marcus Chapman,
Senior Vice President - Finance and Principal Financial and Accounting Officer -
Dr. John G. Aunins Ph.D.,
Sr. Advisor -
Dr. Matthew R. Henn Ph.D.,
Exec. VP & Chief Scientific Officer -
David A. Arkowitz M.B.A.,
Exec. VP, CFO & Head of Bus. Devel. -
James R. Weston,
Sr. VP of Regulatory Affairs -
Jayne M. Gansler,
Exec. VP & Chief People Officer -
Jeff York,
VP of HR -
Noubar Flagship Ventures Fu...,
-
Peter Barton Hutt,
Director -
Michele Trucksis,
See Remarks -
David N Cook,
See Remarks -
Noubar Afeyan,
Director -
Health Science Us Holdings,...,
-
Lorence H. Kim,
Director -
Wael Hashad,
EVP & Chief Commercial Officer -
Teresa L. Young,
See Remarks -
Paula Cloghessy,
See Remarks -
Marella Thorell,
See Remarks -
Roger Pomerantz,
President and CEO -
Kevin Horgan,
Chief Medical Officer and EVP -
Werner Cautreels,
Director -
Noubar Flagship Ventures Fu...,
-
Ventures Fund Iv General Pa...,
-
Health Ltp Fund General Par...,
-
David Arkowitz,
Chief Financial Officer -
Health Ltp Fund General Par...,
-
Claire Fraser,